B of A Securities analyst Tim Anderson has maintained a Neutral rating on Johnson & Johnson (NYSE: JNJ) while raising the price target for the stock. The new target stands at $263, an increase from the previous $254.

Rating and Price Target

The brokerage firm adjusted its valuation outlook for the healthcare giant, signaling a modest upside potential based on the revised price objective. The decision to maintain a Neutral stance suggests that the stock is expected to perform largely in line with the broader market or sector averages.

Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) approved the Dual Energy THERMOCOOL SMARTTOUCH SF Platform (DE STSF), an integrated catheter ablation solution that enables electrophysiologists to deliver both radiofrequency (RF) and pulsed field (PF) energy through a single catheter. This approval allows physicians to tailor treatment based on patient anatomy and case complexity, expanding access to technology previously introduced in Europe. The platform is built on the THERMOCOOL SMARTTOUCH SF Platform, which has treated over one million patients in the U.S.

The DE STSF platform is integrated with the CARTO ecosystem, including advanced mapping, imaging, and PF Index guidance. This integration helps physicians confidently deliver energy with precise contact force while supporting a predictable procedure and reproducible workflow. The dual energy capability provides the versatility to use RF or PF energy based on specific clinical needs.

Clinical and Operational Benefits

The platform combines pulse field and radiofrequency energy in a single catheter, offering a comprehensive solution for electrophysiologists. The CARTO system integration supports complex case planning and execution.

Executive Commentary

"The FDA approval of the Dual Energy THERMOCOOL SMARTTOUCH SF Platform is another important milestone in what has been an incredible pace of innovation for our business," said Michael Bodner, Company Group Chair, Electrophysiology & Neurovascular, MedTech, Johnson & Johnson. "Our goal has always been to put the best possible technologies into physicians’ hands so they can treat increasingly complex cases with confidence. Following a successful introduction in Europe, we’re pleased to rapidly expand access to this technology in the U.S. and continue building on the momentum of one of the most active innovation periods in our history."

Dhanunjaya (DJ) Lakkireddy, M.D., FHRS, MBA, Executive Medical Director at The Kansas City Heart Rhythm Institute, emphasized the clinical utility of the dual energy approach. "The Dual Energy THERMOCOOL SMARTTOUCH SF Platform gives electrophysiologists the choice to use RF or PF energy based on the needs of each procedure. Having both capabilities integrated in the CARTO system can help us adapt our approach for more complex cases and plan procedures with greater confidence."

Commercial Rollout

Following the FDA approval, Johnson & Johnson will initiate a phased commercial rollout. First U.S. procedures with the DE STSF Platform are expected to begin this summer.